| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Z Zhao | |
| M S Edwards | |||
| B L Barber | |||
| D P Sykes | |||
| S D Chadda | |||
| P2860 | cites work | Anti-angiogenic therapies for metastatic colorectal cancer | Q24241813 |
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| NCCN Clinical Practice Guidelines in Oncology: colon cancer | Q35002984 | ||
| Towards a pan-European consensus on the treatment of patients with colorectal liver metastases | Q36563821 | ||
| Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab | Q36616703 | ||
| Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group | Q36927159 | ||
| Guidelines for the detection and treatment of liver metastases of colorectal cancer. | Q37022666 | ||
| Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination | Q37252031 | ||
| Treatment of the elderly colorectal cancer patient: SIOG expert recommendations | Q37298994 | ||
| Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel | Q37372198 | ||
| Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489137 | ||
| Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489147 | ||
| An international, multidisciplinary approach to the management of advanced colorectal cancer. International Working Group in Colorectal Cancer | Q41648027 | ||
| Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q45073835 | ||
| Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. | Q52930698 | ||
| Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. | Q53522081 | ||
| ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer | Q57278937 | ||
| ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer | Q57278942 | ||
| Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy | Q59884573 | ||
| Improving resectability of hepatic colorectal metastases: expert consensus statement | Q80218589 | ||
| Practice parameters for colon cancer | Q80861412 | ||
| Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q81215191 | ||
| Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates | Q81712809 | ||
| Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy | Q82732619 | ||
| NCCN Clinical Practice Guidelines in Oncology: rectal cancer | Q84562586 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 2 | |
| P921 | main subject | monoclonal antibody | Q422248 |
| medical guideline | Q878041 | ||
| systematic review | Q1504425 | ||
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| immunologic factor | Q50349184 | ||
| colorectal neoplasm | Q58833976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e31-47 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Colorectal Disease | Q15764230 |
| P1476 | title | A systematic review of treatment guidelines for metastatic colorectal cancer | |
| P478 | volume | 14 |
| Q38741208 | A Review of the Literature on Multiple Co-occurring Symptoms in Patients With Colorectal Cancer Who Received Chemotherapy Alone or Chemotherapy With Targeted Therapies |
| Q26782245 | A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer |
| Q54333645 | A growing role for Aurora A in chromosome instability. |
| Q60301057 | A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients |
| Q33912255 | Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer |
| Q38556642 | Aflibercept: A Review in Metastatic Colorectal Cancer |
| Q51752412 | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. |
| Q52644017 | CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. |
| Q36261585 | Circadian gene expression predicts patient response to neoadjuvant chemoradiation therapy for rectal cancer |
| Q58761759 | Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients |
| Q42255078 | Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report |
| Q93012652 | Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway |
| Q58695934 | Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer |
| Q37717519 | Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status |
| Q37221691 | Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer |
| Q92278652 | Durable complete response in a patient with metastatic left-sided colon cancer treated with 5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report |
| Q90671111 | Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer |
| Q36112303 | Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis |
| Q50090153 | Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil |
| Q34645505 | Gastroenteropancreatic neuroendocrine tumour arising in Meckel's diverticulum coexisting with colon adenocarcinoma. |
| Q35722688 | Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer |
| Q37135777 | Indole-3-carbinol induces tumor cell death: function follows form |
| Q38075848 | Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review |
| Q42469909 | Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells |
| Q36021018 | Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo |
| Q21133613 | Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model |
| Q38552402 | MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. |
| Q36545995 | Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways |
| Q26828735 | Molecularly targeted drugs for metastatic colorectal cancer |
| Q47769444 | Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial |
| Q90671121 | Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients |
| Q38737059 | Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). |
| Q37997086 | Promoter CpG island methylation markers in colorectal cancer: the road ahead |
| Q38163598 | Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. |
| Q92638558 | Short-term Outcomes After Upfront Chemotherapy Followed by Curative Surgery in Metastatic Colon Cancer: A Comparison With Upfront Surgery Patients |
| Q49127329 | Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases |
| Q37987723 | T-cell-receptor-like antibodies - generation, function and applications |
| Q37993753 | Translation initiation in colorectal cancer |
| Q58595670 | Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases |
| Q36414386 | eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer |
Search more.